GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis
EPA:ALGEN - Euronext Paris - Matif - FR0004053510 - Common Stock - Currency: EUR
Overall ALGEN gets a fundamental rating of 5 out of 10. We evaluated ALGEN against 65 industry peers in the Biotechnology industry. ALGEN has only an average score on both its financial health and profitability. ALGEN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
ALGEN had positive earnings in the past year.
ALGEN had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ALGEN reported negative net income in multiple years.
In multiple years ALGEN reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 3.96%, ALGEN is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
ALGEN's Return On Equity of 7.06% is fine compared to the rest of the industry. ALGEN outperforms 80.00% of its industry peers.
The Return On Invested Capital of ALGEN (6.13%) is better than 84.62% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ALGEN is significantly below the industry average of 12.12%.
The last Return On Invested Capital (6.13%) for ALGEN is above the 3 year average (5.56%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROIC | 6.13% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
1.3 Margins
ALGEN has a Profit Margin of 5.86%. This is in the better half of the industry: ALGEN outperforms 78.46% of its industry peers.
ALGEN has a better Operating Margin (8.09%) than 81.54% of its industry peers.
ALGEN has a Gross Margin of 92.34%. This is amongst the best in the industry. ALGEN outperforms 90.77% of its industry peers.
In the last couple of years the Gross Margin of ALGEN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALGEN is destroying value.
ALGEN has less shares outstanding than it did 1 year ago.
ALGEN has more shares outstanding than it did 5 years ago.
ALGEN has a better debt/assets ratio than last year.
2.2 Solvency
ALGEN has an Altman-Z score of 2.56. This is not the best score and indicates that ALGEN is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.56, ALGEN is doing good in the industry, outperforming 70.77% of the companies in the same industry.
The Debt to FCF ratio of ALGEN is 1.41, which is an excellent value as it means it would take ALGEN, only 1.41 years of fcf income to pay off all of its debts.
ALGEN has a better Debt to FCF ratio (1.41) than 93.85% of its industry peers.
ALGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
ALGEN has a Debt to Equity ratio (0.26) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Altman-Z | 2.56 |
ROIC/WACC0.83
WACC7.41%
2.3 Liquidity
ALGEN has a Current Ratio of 1.92. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.
ALGEN has a Current ratio of 1.92. This is comparable to the rest of the industry: ALGEN outperforms 50.77% of its industry peers.
A Quick Ratio of 1.81 indicates that ALGEN should not have too much problems paying its short term obligations.
ALGEN has a Quick ratio of 1.81. This is comparable to the rest of the industry: ALGEN outperforms 46.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 18.41% over the past year.
Looking at the last year, ALGEN shows a quite strong growth in Revenue. The Revenue has grown by 10.04% in the last year.
ALGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.46% yearly.
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
3.2 Future
ALGEN is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -14.50% yearly.
The Revenue is expected to grow by 10.37% on average over the next years. This is quite good.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y-14.5%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 15.24 indicates a correct valuation of ALGEN.
Compared to the rest of the industry, the Price/Earnings ratio of ALGEN indicates a rather cheap valuation: ALGEN is cheaper than 86.15% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.45, ALGEN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.24 | ||
| Fwd PE | N/A |
4.2 Price Multiples
92.31% of the companies in the same industry are more expensive than ALGEN, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ALGEN is valued cheaply inside the industry as 96.92% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.7 | ||
| EV/EBITDA | 5.34 |
4.3 Compensation for Growth
The decent profitability rating of ALGEN may justify a higher PE ratio.
ALGEN's earnings are expected to decrease with -14.50% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y-14.5%
5. Dividend
5.1 Amount
No dividends for ALGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALGEN (7/4/2025, 7:00:00 PM)
3.2
-0.05 (-1.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners9.39%
Ins Owner ChangeN/A
Market Cap30.34M
Analysts86.67
Price Target6.02 (88.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)-100%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.24 | ||
| Fwd PE | N/A | ||
| P/S | 1.42 | ||
| P/FCF | 6.7 | ||
| P/OCF | 4.39 | ||
| P/B | 1.71 | ||
| P/tB | 2.49 | ||
| EV/EBITDA | 5.34 |
EPS(TTM)0.21
EY6.56%
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.48
FCFY14.94%
OCF(TTM)0.73
OCFY22.77%
SpS2.26
BVpS1.88
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROCE | 7.62% | ||
| ROIC | 6.13% | ||
| ROICexc | 7.79% | ||
| ROICexgc | 11.35% | ||
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% | ||
| FCFM | 21.15% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score5
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Debt/EBITDA | 0.77 | ||
| Cap/Depr | 55.06% | ||
| Cap/Sales | 11.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 114.18% | ||
| Profit Quality | 360.76% | ||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | 2.56 |
F-Score5
WACC7.41%
ROIC/WACC0.83
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y-14.5%
EPS Next 5YN/A
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y0.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year172.73%
EBIT Next 3Y63.41%
EBIT Next 5YN/A
FCF growth 1Y308.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1010.09%
OCF growth 3YN/A
OCF growth 5YN/A